Fountainheadinvesting

Categories
Media

Buying Netflix (NFLX): A Bet on Operating Margins and Revenue Growth

There are some fears of the lack of transparency for the next quarters till analysts and investors get used to not seeing subscriber numbers, but operating margins are improving further, revenues are guided to 14% mid-point growth and earnings should increase 25% per year in the next 3. The stock is down 13% from its all-time high.

Netflix Q1-2024

Beats all around, and has better guidance as well.

GAAP EPS of $5.28 beats by $0.76.

Revenue of $9.37B (+14.8% Y/Y) beats by $90M.

Global streaming paid memberships: +9.33M to 269.6M. UP 165 YoY, Q1 is seasonally low, and in Q1-23, the YoY growth was inly 4.9% so this is quite impressive.

Q2 Guidance: Revenue of $9.49B vs. $9.28B consensus, 16% growth, 21% F/X neutral growth.

EPS of $4.68 vs. $4.54 consensus.

For the full year 2024, we expect healthy revenue growth of 13% to 15%, based on F/X rates at the end of Q1’24. 

We now expect an FY24 operating margin of 25%, based on F/X rates as of January 1, 2024, up from our prior forecast of 24%. 

It’s dropped 3% after hours, (of course,)

Categories
Market Outlook

Market Analysis: S&P 500’s Recent Decline and Interest Rate Implications

S&P 500 5,022 down 243 points, 4.6% from its all-time high of 5,265.

10-Year US Treasury 4.6%, possibly breaching its Oct 2023 high of 4.98%

There has been a lot of consternation regarding the market in the last two weeks, with the index dropping almost 5% and the 10-year jumping from 4.25 to a high of 4.67% because of the fear of higher for longer interest rates due to stubborn inflation and the reluctance of the Fed to cut rates till they put the inflation genie back in the bottle for good.

Let’s look at it chronologically from Oct 2023.

In late October 2023, when the 10-year was close to breaching 5% Janet Yellen signaled lower interest rates by borrowing $76Bn less than anticipated for the last quarter of 2023.  A nod to the nasty run-up in rates, which if unfettered could have been harmful to the economy. The Feds had stopped raising interest rates after the last quarter-point raise in July, and by October, the consensus viewpoint was developing that the markets had done the Fed’s work with the 10-year treasury circling 5%. 

Around the same time, multiple Fed officials had said rising Treasury yields are indicative that financial conditions are tightening, possibly making additional rate hikes unnecessary, when the 10-year Treasury yield topped 4.9% on Wednesday, a first since 2007. During this run-up in interest rates, the S&P 500 had dropped to 4,120 from its July high of 4,560.

Once the 10-year treasury topped out, and Q3 2023 earnings season also exceeded expectations it set up the S&P 500 for a furious run up from the October low of 4,120 to about 4,800 by Dec 2023. A massive gain of almost 700 points or about 17%! helped by the Dec dot plot indicating possibly 3 cuts in 2024

We had another positive run in Q1, to the all-time high of 5,265 – both on AI-related earnings and expectations of the 3 cuts materializing in 2024.

My takeaways

  • A drop of 4.6% compared to the rise from 4,120 in October to 5,265 (28%) is an overdue correction, not a reason to panic.
  • The earnings yield of the S&P 500 = $245/5,022 = 4.9%, which is just above the 10-year treasury yield of 4.6% – we’re getting just 0.3% higher for a riskier investment compared to a risk-free investment of a government security. That’s a very small risk premium, I would think the S&P 500 is likely to fall further to see some semblance of the historic and mean premium of at least 1 to 1.5%.
  • The same argument that the Fed used in October is likely to happen as the treasury inches towards 5% – 
  • a) the market itself has made financial conditions worse, (done the Fed’s work – a 0.6% rise in the treasury is more than 2 quarter-point hikes!) 
  • b) Buying a risk-free (US Government) long-duration bond paying 5% is a damn good yield and when funds start buying bonds, the yields fall. There will be buyers from all over the world for that kind of yield. Especially in the event of further turmoil in the Middle East – that’s the flight to quality and safety. I don’t see yields topping 5% – I would be shocked if it did.
  • The Vix (Volatility Index) or the fear gauge as it is known has shot up to 18-19, after being dormant to steady in the 12 to 14 range through Q1-2024. Computerized trading desks or CTA’s, trade based on volatility which will cause sudden drops and a lot of choppiness, which scares investors. Zero-day options are not helping either. For example, if I see a 1% down day, my first reaction is to lower my buying limits.
  • Earnings season should be good, but misses are likely to be hammered disproportionately given the weakness in the market. Semiconductor monopoly ASML, which missed bookings but assured the same full-year guidance and a great 2025, dropped 8% today.
  • The graph below is a good contrarian indicator and makes me shake my head at supposedly professional investors. Fund managers have record low cash levels – they’re overextended at only 4.2% cash. When they need the money to pick up bargains, they don’t have it! Some professionals! This won’t help the market recover easily.
  • This is another good chart.

If Q1 has risen more than 10%, on every occasion except 1987 (the year of the Black Monday crash) it has closed the year higher. That doesn’t preclude drawdowns and the average pullback in the years was 11%, with a low of 3%.

  • I feel the best way to play this uncertainty is patience and lower limits – the first quarter was exceptional and unlikely to be replicated. 

 THE LONG-TERM STORY FOR QUALITY STOCKS IS VERY MUCH INTACT, but we would be better off getting good prices. The first to recover will be the high-level quality stocks – see how steady Microsoft is compared to the rest. 

  • In the last 15 days, my buy trades and recommendations have been limited as you may have noticed and strictly averaging lower with lower limits. I intend to keep it that way.
Categories
Healthcare

Solventum (SOLV) Stock: A Wait-and-Watch Story Amidst Growth Concerns

Solventum (SOLV) $62.75

Two Wall Street firms Wells Fargo and Morgan Stanley have similar advice to what I gave about Solventum in my earlier post. Growth concerns will keep the stock flat.

It’s a wait-and-watch story.

Here’s the Barron’s link.

https://www.barrons.com/articles/solventum-stock-price-3m-spinoff-4f6025e7?mod=md_stockoverview_news

Categories
Market Outlook

The Macro Approach And Historic Valuations;. Are We Overpriced?

Top down-market strategy is relevant and sometimes essential when you want to compare the S&P 500 against historical benchmarks. I did this in a series of articles for Seeking Alpha from Dec 2022 to June 2023 and spoke about the same things that market outlook strategists do – historical valuations, poor market breadth, interest rate correlations, smaller categories dominating, and future earnings being misleading especially when they start to falter. I still pretty much look at the macro backdrop every week even now, but it’s a great backdrop, an important framework and benchmark but not a primary factor or thesis for making individual stock decisions. I stopped doing the market outlook top-down series a while ago, when I realized I should get back to my roots and focus on fundamentals getting into the weeds, rather than trying to get better returns by forecasting market direction. As an example, in April-June 2023, I was trying to predict a 3-5 % correction in the S&P 500 when the AI revolution was happening in companies like Microsoft and Nvidia right before my eyes, again ironic because my first article recommending Nvidia was in October 2022.

And that’s been the story for the better part of 3 decades – more success in fundamentals than macro/market direction and technical analysis.

There are several bearish top down-market prognosticators talking about the overpricing of the current market with equally good rebuttals from the bull camp – the correlation with the Nifty Fifty gets the most pushback as does with the 1999 internet bust. There is the concern about poor market breadth with tech stocks hogging too much of market cap and profits, with the rebuttal being the GFC peak. In the 2007-2008 Great Financial Crisis bust, the financial sector had the highest concentration of the S&P 500; financials are typically cyclical with P/E’s rarely exceeding 12-14, and then they were at 20, with expectations of 25% growth, their debt-to-equity ratios were like 33:1 That was an example of ABSURD overpricing! 

The point is – it is extremely difficult to compare and predict the bull market euphoria peaks, and to a great extent that time is better spent getting into the weeds of individual stocks and also using the macro backdrop as a variable but not the prime one. Also, how are we going to make better returns trying to time the S&P 500, through downturns or predicting bubbles?

A great company bought at a good price will also go through a drop when the market turns bad – sometimes only because the sentiment has turned and more often on its own demerits and reduction in earnings power, often we’ve overpaid or not taken profits when the going was good. There is no escaping the inevitable downturn, and we try our best to mitigate it. Profit taking is important, not chasing momentum is important; Not overpaying is equally important. Buying quality companies is very, very important. Diversification is important, I do want to have less tech or AI stocks and am always looking out for good ones in other sectors, without getting into value traps just because they’re cheap. There are a bunch of strategists who’re advising buying the Russell 2000 as a de-risking strategy because the gap between the valuations of the Russell 2000 and the Nasdaq 100 is the widest in decades. There is some merit in that, but de-risking is a strange way to put it, because by definition the Russell 2000 has the biggest loss making stocks with the highest earnings risk, and the highest weighting in it is the overpriced SuperMicro (SMCI)!

In terms of macro strategy, I like using the FactSet S&P 500 monthly earnings report, which I follow for the broader Price/ Earnings multiple, earnings and earnings growth. In my opinion, the market is overpriced by about 10% for sure, the last decade’s P/E ratio was about 18-19, we’re at 21 now, with the Index at 5,100 / $245 earning per share. 

If you look at the earnings yield of the S&P 500 it is $245 per share / index of 5,100 = 4.8%. The first question you would ask is why am I investing in the market when the 10-year risk free treasury gives me 4.4%, what, am I getting only 0.4% extra for the extra risk?? The historical risk premium in the last two decades has been closer to 1.5%. Even though I ran the numbers from 1962 the other decades have their own idiosyncratic reasons and are not comparable.

In late December 2023, early Jan 2024, I did expect the 10-year treasury interest rates to stay range bound between 3.75% to 4%, with a downward trend moving to 3.25 to 3.5% by the end of 2024, equating to a risk premium of about 1% – given the AI euphoria I wasn’t expecting anything better, and markets do tend to lead, always expecting better times. That hasn’t happened and we’re instead at 4.4% today, which has put a cap on the index and rightly so.

Bottom line – We are slightly overbought and likely to see sluggishness in the index and that reinforces my focus on still finding great companies at bargains, bargains are even more important now.

Categories
Healthcare

Humana: A Healthcare Giant Facing Challenges but Offering Long-Term Value

Humana (HUM) $302

Humana has fallen 40% in the past year to $302, after lower guidance and missing estimates, and 14% today, after a lower than expected reimbursement rate from Medicare Advantage, where it is the second largest player. Losses have extended to major players like United Health as well.

Revenue projections for the next three years on lower MA payments are already down to low single digits 2-4%.

However, Humana has better operations than most, better cost control and profit margins while low, are still better than other providers. It should have better growth in 2025, and consensus estimates are calling for $24 earnings per share and mid twenties earnings growth from such a low base. Most of this is already in the price.

That said, it is a $112Bn giant, and given how regulated this industry is and how difficult it is to make money, entrenched players like it will survive and recover, but expect 2024 to be volatile, there could be further misses.

It’s worth buying in the $270-$280 range, or starting and accumulating on dips. There is value at the current multiple of only 12x 2025 earnings of $24. It’s below their historical multiple of 15-16.

Returns should be muted though, it’s a healthcare company after all, but the discount should help get over 10% per year, including dividends over the next few years.

Categories
Enterprise Software

Adobe: A Strong Franchise Facing Valuation Challenges Amid Slowing Growth

Adobe (ADBE) – $506

It has strong defensible franchises, great branding and leadership. Very profitable in all its segments with operating margins in excess of 30%.

The threat of AI replacing some of the video editing and other products is still in its infancy and Adobe is also working on its own AI initiatives; they’ve just been slow to roll it out.

Revenue growth has slowed to 10-12% for the next three years, and management did disappoint for the next quarter’s guidance. However, Adobe is also a good earnings story with 13-14% earnings growth.

The only problem is the valuation, and the market perception that this is a mature company with $20Bn in revenue. At 28x earnings and 10.5x sales there’s not much left for appreciation with that slowing growth.

I would prefer to buy on declines at around $470. At $506 I would expect a return of about 12% or so a year.

Categories
Semiconductors

Marvell Technology: Positioned for AI Growth but Priced for Perfection

Marvell Technology (MRVL) $74

Networking infrastructure – It had a down year, with cyclicality in China and slower data center growth. China is about 50% of revenues.

That said, the forecast for the next three years is good, with 24% revenue growth and 35 to 40% adjusted earnings growth. 

A lot of this is riding on growth from Nvidia and other AI investments in data centers. 

Like most companies in the sector Marvell has also appreciated 73% in the past year so valuations are a bit expensive, 11x sales, with cyclicality and China exposure, it’s definitely on the higher side. It has also financed its acquisitions with debt, carrying a lot of interest burden.

I would prefer to buy 10% lower in the mid sixties for a better return – there is an AI event on April 11th, which may have more specifics/catalysts. Will keep a look out for that.

Categories
Leisure

Disney’s Rebound: A Hold for Steady Returns, but Limited Upside

Disney (DIS) $122 Hold

Disney bounced back strongly in the last 12 months gaining 28% and 50% from its October now, a commendable rise reflecting the efforts of management to turn it around.

Going forward total revenues should be muted around 4 to 5% after the last three years gain of 8%. Entertainment and sports are slow growers, theme parks grew a lot after the pandemic ended, but won’t have that tailwind on a higher base.

Streaming while plateauing in the US will grow abroad, but the sluggish growth will not allow for major price increases. Besides Netflix and Prime, they should be the 3rd survivor, WSJ research indicated that there was resistance beyond 3 subscriptions per home.

Disney used to have over 20% operating margins, now they are like 10-11%, ESPN weakness, theme park shutdowns during the pandemic and all the expense of streaming really killed margins, but they are turning it around and the Dec quarter showed improvement.

Earnings will grow around 13% –  that’s the biggest positive, the brand value is tremendous and Disney will carry a premium multiple.

Valuation – Disney is already priced at 26x earnings, twice its growth rate, mainly because of the 28% gain in the past year. I would expect at least a 22-24 multiple of FY 2027 earnings of $7- that’s about $160-$170 per share, three years out, that’s a 10% return per year from the current price.

A good hold if 10% a year is good enough, I wouldn’t add more unless there is a major drop in price or a big improvement in strategy. 

Categories
Enterprise Software

nCino: A SaaS Player Focused on Profitability but Facing Valuation Hurdles

nCino Inc (NCNO) $35.75

The stock jumped 15-20% post earnings on an earnings beat and slight revenue miss, from $30 yesterday. Guidance is also decent with 15% revenue growth for 2024.

You could buy around $32 or in installments.

Positives

Focusing on profitability, makes decent cash flow of 15% and adjusted operating of 3-5%, showing an improving trend with good estimates of earnings improving 35% in years 2025-2026. 

They have the leverage to do that, it’s a SaaS business but I would have preferred gross margins in the high 80’s. That must happen over time.

They are selling to higher cohort customers, growth in customers over 100K and $1Mn is much higher than baseline growth.

There is a switching cost competitive advantage, especially when you’re dealing with larger customers, and have more than one offering.

Negatives

Sales cycles are longer given the higher value customer.

Banking and financial services software is very competitive, not much to differentiate from one another.

Price has gotten a little expensive at 6x sales with 15% revenue growth so returns going forward will be muted in comparison.

Given the weaknesses in banks and the financial services sector, I don’t expect multiples to be more rewarding than the market, even though this is a tech company, but focused on one vertical.

Categories
Fintech

Pagaya: Navigating Capital Raise Challenges While Aiming for Profitability

Pagaya (PGY)

It was an interesting call and some questions were answered, which is kind of normal for these meetings. 

  • Guidance is reaffirmed for Q1-24 and full year 2024, which is about $170Mn in adjusted EBITDA.
  • Pagaya will be operating cash flow positive in early 2025 – reaffirmed. This was given with enough specifics, there will be enough margins from credit lending to tide over retention requirements.
  • There was a certain amount of naivete about getting a good deal from Wall Street for the recent capital raise, from both Pagaya and several of us bullish analysts. Wall Street never overpays and Blackrock, most definitely never does. And as the market was driven down, two other institutions besides Blackrock, who were part of the raise also bargained much lower than the original price. 
  • In terms of risk – there was a fair amount of detail provided on 2021-2022 vintages, which had weaker loans than 2023 and current cohort, but management again reiterated that this was significantly lower than the rest of the market. I suspect that this weakness was well taken advantage of by the investors in the current capital raise.
  • In securitization even though the issuer has to retain only 5% for compliance, the performance of the loans still matters because the underwriter will not come back to you as the issuer keep piling on bad loans, and because securitizations work in tranches – the top tranche has the best loans and so on, the weaker tranches cannot afford to have too many delinquent loans..in which case the issuer will have to take up that slack to just to stay in business. The general impression we got was that some of the 2021 vintage was slow to be taken off the books at a decent price.
  • Bottom line – I’m staying invested till the next quarters’ earnings call in May.
  • I have submitted these questions:

“1) Please address the surprise, blindsiding nature of the capital raise (3 days after the Reverse Split). Also, the midstream lowering of the price of the offering while increasing the number of shares you offered.

“I believe the original estimate was $14.70, then it was $12.70, and I watched the volume that day of the offering: the majority of it was under $12, and the share price closed a little above $11. Institutional participation seemed hesitant, even lacking. Today the share price is $9.12

“The timing and execution of this offering has been an unmitigated disaster for your shareholders, somewhere around a $600ML loss for a $90ML capital raise.

“How do you square that? Now that the damage has been done, it’s time to be honest with your investors about the capital raise. What happened?

“2) Since the bearish analyst at Wedbush Morgan downgraded your price target to $11.50, while remaining neutral, citing “losses in risk-retention assets” there has been a horde of relatively-inexperienced DYI accountants pouring through your past financial statements, looking for buried losses that you have not explicated for investors.

“You stated them, yes, in the March 8th 20-F, but now the investing world wants an explanation.

“What is the performance of your risk-retention assets? Are they insured? What is their current status? Do you now have sufficient capital to steer Pagaya to the end of the year? And cover the 5% needed for future ABS investments? Can you reaffirm your 1Q24 guidance and your full year estimates? Thank you.”